Ivax Corporation received final approval from the Federal Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for citalopram hydrobromide tablets in 10, 20, and 40 mg dosages.

Citalopram is the generic equivalent of Celexa, which is marketed by Forest Pharmaceuticals for the treatment of depression. According to IMS data, US sales of Celexa 10, 20 and 40 mg tablets were over $1.4 billion for the year ending June 30, 2004. This product will be marketed by Ivax' wholly-owned subsidiary, Ivax Pharmaceuticals Inc.

Ivax Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent pharmaceuticals and veterinary products in the US and internationally.